Tagged with B

Colombia Clara Isabel Rodríguez, Executive Director of the Colombian Association of the Pharmaceutical Industry (ASCIF), shares her journey from public sector leadership to industry advocacy. With deep experience in health regulation and public administration, Rodríguez reflects on Colombia’s pharma landscape, the challenges of ongoing health reform, and why local manufacturing is…

Brazil Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different course, towards innovation, manufacturing sovereignty, and strategic influence. Speaking on behalf of Grupo FarmaBrasil, a coalition of the country’s top…

Global Cell and gene therapies are redefining the boundaries of what is scientifically and operationally possible in healthcare, but bringing these innovations to patients at scale requires more than breakthrough science. In this conversation, Ralf Altenburger, Global Head of Cell & Gene Therapy at Roche, discusses how the company is navigating…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

China Chinese biotech is booming, led by a generation of pioneering individuals at the forefront of science and business.   A country once best known as a low-cost manufacturing destination for ‘me-too’ copycat medicines now accounts for over 28 percent of the global drug development pipeline. Western companies approaching patent cliffs…

Global As the global population ages and the incidence of vision-related conditions rises, ophthalmology is entering a transformative era. Beyond symptom management, the field is moving towards disease modification through cell and gene therapies like optogenetics while boosting artificial intelligence (AI) to speed up pipelines, and developing minimally invasive delivery systems…

China Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a distinguished career at the FDA to establishing one of the most promising lipid nanoparticle delivery platforms in the industry, he…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…

Brazil Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect of the organisation’s strategic transformation. His tenure spans critical periods of regulatory modernisation, digital transformation, and international collaboration, positioning him…

Europe Pharma and biotech companies are doubling down on innovation and, often, outsourcing just about everything else. That shift has turned contract development and manufacturing organisations (CDMOs) into critical partners, not just service providers. The sector is booming, but pressure is building fast: demand is surging, capacity is stretched, and new…

France Julien Ettersperger, appointed in November 2023 as the first internal leader of Medicen, is steering the agency through a strategic transformation to establish Île-de-France as Europe’s leading health innovation hub. Leveraging the region’s dense research capacity, he champions stronger public-private collaboration to better convert scientific excellence into commercial impact. The…

UK The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and why AstraZeneca’s latest US manufacturing investment does little to ease fears that the British firm might choose to relocate across…